Tags

Type your tag names separated by a space and hit enter

Seborrhoeic dermatitis: current treatment practices.
Expert Opin Pharmacother. 2004 Aug; 5(8):1755-65.EO

Abstract

Seborrhoeic dermatitis (SD) is a recurrent, chronic inflammation of the skin that occurs on sebum rich areas such as the face, scalp and chest, characterised by red scaly lesions. The are many studies indicating that Malassezia yeasts play an important role in the aetiology of this condition, most of the evidence for which comes from demonstrated responsiveness to treatment with antifungal agents. Its aetiology, however, is far from being resolved. Some believe that it is the immune response of the skin to the Malassezia that is the cause of the disease. Traditional treatments of SD have been the use of keratolytic agents or corticosteroids. Since the discovery of ketoconazole, a considerable amount of research has been focused on determining the efficacy of various antifungal agents. This article reviews clinical trial data on treatment options available for SD.

Authors+Show Affiliations

Division of Dermatology, Department of Medicine, Sunnybrook and Women's College Health Science Center (Sunnybrook site) and the University of Toronto, Toronto, Canada. agupta@execulink.comNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

15264990

Citation

Gupta, Aditya K., and Nataly Kogan. "Seborrhoeic Dermatitis: Current Treatment Practices." Expert Opinion On Pharmacotherapy, vol. 5, no. 8, 2004, pp. 1755-65.
Gupta AK, Kogan N. Seborrhoeic dermatitis: current treatment practices. Expert Opin Pharmacother. 2004;5(8):1755-65.
Gupta, A. K., & Kogan, N. (2004). Seborrhoeic dermatitis: current treatment practices. Expert Opinion On Pharmacotherapy, 5(8), 1755-65.
Gupta AK, Kogan N. Seborrhoeic Dermatitis: Current Treatment Practices. Expert Opin Pharmacother. 2004;5(8):1755-65. PubMed PMID: 15264990.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Seborrhoeic dermatitis: current treatment practices. AU - Gupta,Aditya K, AU - Kogan,Nataly, PY - 2004/7/22/pubmed PY - 2005/6/28/medline PY - 2004/7/22/entrez SP - 1755 EP - 65 JF - Expert opinion on pharmacotherapy JO - Expert Opin Pharmacother VL - 5 IS - 8 N2 - Seborrhoeic dermatitis (SD) is a recurrent, chronic inflammation of the skin that occurs on sebum rich areas such as the face, scalp and chest, characterised by red scaly lesions. The are many studies indicating that Malassezia yeasts play an important role in the aetiology of this condition, most of the evidence for which comes from demonstrated responsiveness to treatment with antifungal agents. Its aetiology, however, is far from being resolved. Some believe that it is the immune response of the skin to the Malassezia that is the cause of the disease. Traditional treatments of SD have been the use of keratolytic agents or corticosteroids. Since the discovery of ketoconazole, a considerable amount of research has been focused on determining the efficacy of various antifungal agents. This article reviews clinical trial data on treatment options available for SD. SN - 1744-7666 UR - https://www.unboundmedicine.com/medline/citation/15264990/Seborrhoeic_dermatitis:_current_treatment_practices_ DB - PRIME DP - Unbound Medicine ER -